TQB3205
/ Sino Biopharm
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 11, 2026
Sino Biopharmaceutical Limited…announces that TQB3205 ’pan-KRAS inhibitor’, a national Category 1 innovative drug independently developed by Chia Tai Tianqing Pharmaceutical Group,…has received the clinical trial approval from China’s National Medical Products Administration (NMPA) for the intended treatment of advanced malignant tumors
(HKEXnews)
New trial • Solid Tumor
1 to 1
Of
1
Go to page
1